Three different classes of Fc receptors for IgG (FcyR) are currently distinguished in humans, of which polymorphonuclear phagocytes (PMN) normally express both low-affinity receptor classes-FcyR11 (CD32) and FcyRlll (CDI 6). During therapy with granulocyte colony-stimulating factor (G-CSF), neutrophils from patients with various malignancies and different hematologic disorders werevfound to additionally express high levels of the receptor with high affinity for IgG (FcyRI; CD64). For these patients, the relative fluorescence intensity (rFI) for FcyRl was 5.3 (range, 1.7 to 10.3; n = 19) . compared with 1 .O (range, 1 .O to 1.1 ; n = 8) for healthy donors. The expression of FcyRl during G-CSF therapy could be confirmed by using a panel of six CD64-specific antibodies, and by showing mRNA for FcyRI. So far, three genes for FcyRl have been identified, encoding four distinct transcription products. By reverse transcriptase-polymerase chain reaction technology, tran-OR THE DEFENSE against invading micro-organ-F isms, a complex network of humoral and cellular components exists. Within this system, receptors for the constant part of Igs (Fc receptors) play a central role connecting the specific humoral immune response to the phagocyte compartment. By molecular and functional analysis, three distinct classes of Fc receptors for IgG can be distinguished'*2: one with high affinity for IgG (FcyRI; CD64) and two classes that interact well only with complexed IgG (FcyRII, CD32; and FcyRIII, CD16). Eight different genes have been identified to encode the members of these FcR classes. All genes have been located to the long arm of chromosome 1 : FcyRI on lq2 I. I and FcyRII and FcyRIII on lq23-24.' For FcyRI, three different genes (FcyRIA, FcyRIB, and FcyRIC) exist that encode four distinct transcription products. From the prediction of molecular analysis, only FcyRIa and FcyRIb2 give rise to transmembrane receptors, whereas FcyRIb 1 and FcyRIc presumably encode soluble product^.^ Expression of FcyRI was found to be restricted mainly to mononuclear phagocytes, but polymorphonuclear phagocytes (PMN) can express FcyRI in certain clinical situations5~' and after in vitro incubation with interferon-y (IFN-y). ' We recently described FcyRI expression on PMN of patients receiving granulocyte colony-stimulating factor (G-CSF) after chemotherapy for head and neck cancer. ' We show here that expression of FcyRI is a characteristic feature of PMN during therapy with this cytokine.
Decreased granulocyte counts (due to chemotherapy or to primary hematologic disorders) are associated with an increased risk of bacterial or fungal infections." Therefore, clinical application of hematopoietic growth factors, which regulate the proliferation and differentiation as well as the functional activity of myeloid cells, is under intensive investigation. Among this expanding family of glycoproteins, G-CSF has shown its capability to ameliorate neutropenia and its sequelae."*'* Although in vitro incubation of PMN with scripts for both membrane-associated isoforms (hFcyRla and hFcyRlb2) could be detected. The functional activity of FcyRl on PMN during G-CSF therapy was shown by measuring binding of monomeric human lgG and antibody-dependent cellular cytotoxicity (ADCC). Thus, FcyRI-positive neutrophils displayed enhanced ADCC activity to glioma ( A I 207). squamous cell (A431 ), and ovarian (SK-ov3) carcinoma cell lines. The involvement of FcrRl in this increased cytotoxic activity was shown by blocking Fcy receptors with monoclonal antibodies, and by using F(ab' ), X F(ab),-bispecific antibodies with specificities against tumor-related antigens and FcyRI, resulting in solely FcyRI-mediated cytotoxicity. Therapeutically, this additional Fc receptor on PMN may increase the efficacy of experimental antibody therapy. G-CSF does enhance the functional activity of PMN in different assays,I3 no major change in Fc receptor expression, especially no significant induction of FcyRI, could be observed after in vitro incubation.' After in vitro induction by IFN-y, FcyRI on PMN mediates phagocytosis, generation of the oxidative burst, and tumor cell cytotoxicity,* supporting a role as an important trigger molecule on PMN.
Therapeutically, a combination of G-CSF and antibodies may be promising for the management of certain infections. In addition, expression of FcyRI may increase the interest in neutrophils as putative effector cells in a concept of targeted cytot~xicity.'~ Neutrophils can lyse a variety of different tumor cell lines, but also tumor cells obtained from patient^.'^ As shown here, PMN-mediated tumor cell cytotoxicity is enhanced during G-CSF application directly involving FcyRI as a cytotoxic trigger molecule.
MATERIALS AND METHODS

Monoclonal Antibodies (MoAbs)
Irrelevant antibody (IgG2a), used as a control in immunofluorescent analyses, was produced from the hybridoma clone 10. SATA derivatization of F(ab'), fragments of MoAb 520C9 was performed by incubating0.2 pmol(30 mg) of MoAb 520C9 in 5 mL of sodium phosphate-2.5 mmol/L EDTA (buffer), pH 7.4, with 10 times molar excess of SATA (Pierce, Rockford, IL). The reaction was stopped by adding 1 mol/L glycine solution to a final concentration of 0.01 mol/L. Excess SATA and glycine were removed by dialysis against buffer. To expose the -SH group, SATA-derivatized F(ab'), fragments were treated with 50 mmol/L hydroxylamine ( I hour at 2 1 "C), followed by dialysis. Sulfo-SMCC derivatization of F(ab'), fragments of MoAb 22 was obtained by incubating 0.2 pmol(30 mg) of MoAb 22 in 5 mL buffer with 20 times molar excess of Sulfo-SMCC (Pierce). The reaction was terminated as described above. Thioether linkage was formed by incubating SATAderivatized, -SH exposed F(ab'), fragments of MoAb 520C9 and SMCC-derivatized F(ab'), fragments of MoAb 22 at I: 1 molar ratio ( 17 hours at 2 I "C). The reaction was stopped by adding solid NEM to a final concentration of 10 mmol/L for 1 hour. Excess NEM was removed by dialysis.
Target Cell Lines
A 1207 (glioblastoma), originally established by Dr S.A. Aaronson (Laboratory of Cell and Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda), and A43 I (squamous cell ~arcinoma)'~ were kindly provided by Merck and cultured in Dulbecco's medium (GIBCO, Paisley, UK) supplemented with 100 U/mL penicillin, 100 rg/mL streptomycin (GIBCO), 4 mmol/L L-glutamine (GIBCO), and 10% fetal calf serum (FCS; GIBCO). Sk-ov3 (ovarian carcinoma) obtained from ATCC were grown in RPMI 1640 (Seromed, Berlin, Germany) supplemented as Dulbecco's medium (RFIO+), including 0.07 U/mL human insulin (Hoechst, Frankfurt, Germany).
Patients
Patients with advanced (stage 111 or IV) squamous cell carcinoma of the oral cavity and pharynx (head and neck cancer) were treated according to the protocol of the clinical trial GCSF8806. Details of this trial (which was approved by the Institutional Review Board of the Medical Faculty, University of Erlangen-Nurnberg, in accordance with the Declaration of Helsinki) were reported in Repp et al? Since the approval of recombinant human G-CSF (rhG-CSF) by the German Drug Administration, patients with various disorders and different therapies ( Table 1) were treated with rhC-CSF (Neupogen, 3 to 5 pg/kg of body weight) based on clinical indications. In these patients, the kinetics of neutrophil recovery during G-CSF treatment were variable. Therefore, the criteria used to analyze PMN from these patients were defined as ( I ) at least 3 days of G-CSF treatment and (2) absolute neutrophil counts higher than 2,50O/pL. PMN from one patient with cyclic neutropenia were analyzed during either rhG-CSF or recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF) (3.5 pg/kg of body weight; Behring, Marburg, Germany) treatment using the same criteria as above.
Neutrophil Isolation
PMN were isolated by a method slightly modified from that described in Repp et aL9 Briefly, heparin-anticoagulated blood was layered over a discontinuous percoll gradient (Seromed) consisting of two layers of 68% and 63% percoll, respectively. After centrifugation, PMN were harvested from the percoll interphase and the remaining erythrocytes were removed by hypotonic lysis. Cytospin preparations were used to assess the purity of isolated cells, which was higher than 95%, with few contaminating eosinophils. The viability of cells, determined by trypan blue exclusion, exceeded 95%.
1 % bovine serum albumin (BSA), FITC-labeled F(ab'), fragments Northern Analysis of RNA Total cellular RNA was isolated from various cells using the RNA zol B method (Cinna Biotecx, Friendswood, TX) as in Kindt et al. 26 Cell lines used were K562 (FcyRI negative control), U937, and THP-1 (both FcyRI positive). U937 and THP-I were cultured for 24 hours with 100 U/mL IFN-y before RNA isolation. PMN from different patients were isolated as above. Upon isolation, 10 pg of total cellular RNA was fractionated by electrophoresis in 1% agarose/formaldehyde gels and transferred to nitrocellulose (BA85; Schleicher & Schuell, Dassel, Germany). Hybridization with "P-labeled 1.4-kb Xho fragment of cDNA ~1 3 5~' was performed overnight in 50% formamide, 3X SCC, 0.1% sodium dodecyl sulfate (SDS), 1OX Denhardt's solution, with 50 pg/mL denatured Salmon sperm DNA at 42°C. Filters were washed in 0.3X SCC, 0.1% SDS at 42°C for 30 minutes and exposed to Kodak XAR5 (Eastman Kodak, Rochester, NY).
IdentiJcation of Different Gene Products by Reverse Transcriptase-Polymerase Chain React ion (R T-PCR)
Five micrograms of total RNA were reverse transcribed using 17 U of Avian Moloney virus reverse transcriptase (Pharmacia; Uppsala, Sweden) for 90 minutes at 42°C. Incubations were performed in 50 pL with 10 mmol/L MgCl,, 100 mmol/L Tris-HC1 (pH 8.3), 140 mmol/L KC1, 2 mmol/L dithiothreitol (DTT), 0.2 mmol/L of each dNTP, and 100 ng ofNot I-d(T),* primer (Pharmacia). Three microliters of RT-cDNA was added to a PCR reaction (100 pL volume) with I X PCR buffer (Promega, Madison, WI), 0.25 mmol/ L of each dNTP, 10 pmol of each oligonucleotide primer, and 1 U Taq polymerase (Perkin-Elmer, Nonvalk, CT). FcyRI transcripts were amplified using primer 9 (S-ACACCACAAAGGCAGTGA-3'), corresponding to nt 89-106, and primer 10 (5'-CACCCAGAG-AACAGTGTT-3'), corresponding to the reverse complement of nt 952-969 of cDNA ~1 3 5 .~ PCR amplification was performed in an automated thermal cycler (Bio Phase; Bio Excellence, Colchester, UK) using denaturation for 2 minutes, primer annealing at 55"C, and extension at 72°C for 2 minutes (30 cycles). Twenty microliters of PCR products was fractionated by agarose gel electrophoresis and blotted to nitrocellulose. Specific hFcyRIa and Ib products were detected using gene-specific oligonucleotide probes 37A (5'-GAATATCTGTCACTGTGA-3')and 39B( 5'-GAATATCACAAT-ACACTG-3'): Oligonucleotides were 5'-phosphorylated with "P and polynucleotide kinase (Pharmacia).
Neutrophil RT-cDNA samples were checked for potential monocyte contamination by amplification of the c-fms cDNA (encoding the macrophage colony-stimulating factor [M-CSF] receptor), which is expressed in monocytes, but not in PMN?8 We used an exon 19 sense primer (5'-TCACTTGGGCTGAATCCCTA-3') and an exon 22 antisense primer (T-TCCCTGTCGTCAACTCCTCA-3). PCR amplification was performed exactly as in Kaashoek et a129 and never yielded the characteristic 389-bp c-fms band in any RTcDNA sample derived from RNA isolated from PMN from G-CSF patients.
Binding ofHuman IgG
Neutrophils were isolated as above and incubated in RPMI for 3 hours (37°C; 5% CO2) and cells were washed twice with RPMI 1640. Cells were divided into two fractions, one was incubated (30 minutes at 4°C) in RPMI 1640 alone and the other was incubated with RPMI 1640 and monomeric polyclonal human IgG (20 pg/ mL; ultracentrifuged at 100,000g for 1 hour). After washing once, cells were stained with FITC-conjugated F(ab') fragments specific for human IgG. Fluorescence intensity was quantitated by flow cytometry.
Antibody-Dependent Cellular Cytotoxicity (ADCC) Assays
Cytotoxicity assays were performed as described.M Briefly, target cells (A 1207, A43 1, or Sk-ov3) were labeled with 51Cr (100 pCi for 3 hours) and sensitized by saturating concentrations of MoAbs as determined by immunofluorescence. MoAb 425 (20 pg/mL) to the EGF receptor was used for A1207 and A431. For SK-ov3, either bispecific F(ab'), X F(ab), antibody 520C9 X 22 (20 pg/mL) or an equimolar mixture of unlinked F(ab), fragments of both parental antibodies was used. After incubation oftargets (37°C; 5% CO2 for 30 minutes), cells were washed once and numbers were adjusted to give the desired amount of target cells in 50 pL of RFIO'. Neutrophils (50 pL), target cells (50 pL), and RFIO' were added to a final volume of 200 pL. When indicated, conditioned medium of bladder carcinoma cell line 5637 (50 pL) was added instead of RFlO' during ADCC assays. This conditioned medium is a source of hematopoietic growth factors" and was used to accomplish in vitro stimulation of effector cells. In control experiments, it was found to not be cytotoxic to target cells and to not alter FcyRI expression on PMN. In some experiments, anti-Fcy receptor antibodies (10 pg/ mL final concentration) were added 30 minutes before the addition of targets. Effector to target ratios were 40: I for A 1207 and A43 1 and 80: I for Sk-ov3, which were determined in pilot experiments to give comparable amounts of tumor cell lysis. Assay duration was 3 hours for A 1207 and A43 1 and 18 hours for SK-ov3, starting at the addition of target cells.
The release of label from triplicates was measured and analysed using the formula: 
Statistical Analysis
Statistical differences were analyzed by unpaired Student's t-test or, when appropriate, paired Student's t-test. Significance was accepted when P < .05. Group data are reported as the mean f standard error of the mean (SEM), or as the median and range of the number (n) of experiments, as indicated.
RESULTS
Presence of FcyRI on Neutrophils
Expression of the Fc receptor with high affinity for IgG (FcyRI; CD64) was analyzed on isolated PMN by indirect immunofluorescence staining with MoAb 32.2. Thus, neutrophils of patients receiving G-CSF (3 to 5 pg/kg body weight) expressed
FcyRI expression during G-CSF therapy.
For
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VALERIUS ET AL significantly (P < .01) more FcyRI (median rFI, 5.3; range, 1.7 to 10.3; n = 19) than did PMN from healthy donors (median rFI, 1.0; range, 1.0 to 1.1; n = 8). In this study, PMN from patients with various malignancies and different hematologic disorders were analyzed during G-CSF therapy (Table 1) . So far, all tested patients showed marked expression of FcyRI during G-CSF treatment. PMN from individual patients with different diseases (head and neck cancer, non-Hodgkin's lymphoma [NHL] , and cancer of testis) were analyzed before and during G-CSF application. The results of staining on PMN from these patients for FcyRI (rFI without/with G-CSF) were 1.4/8.4, 0.9/2.3, and 1.5/ 3.4, respectively. Neutrophils from one patient with cyclic neutropenia markedly expressed FcyRI during G-CSF (rFI = 10.7) but not during GM-CSF (rFI = 0.9) treatment. These data support the expression of the high-affinity receptor for IgG to be a characteristic feature of PMN during G-CSF therapy.
Fc receptors are members of the Ig-supergene family consisting of a large number of highly homologous molecule^.^' To test whether binding of MoAb 32.2 to PMN during rhG-CSF therapy was due to cross-reactivity with other members of this family, a panel of six CD64 antibodies was evaluated. Figure 1 shows the results of an experiment comparing PMN from a healthy donor and a patient with high-grade lymphoma receiving G-CSF. Significant binding of anti-CD64-specific antibodies occurred only with PMN during G-CSF treatment. Differences in staining intensities between the various antibodies are in agreement with known differences in binding affinity to FcyRI.17 Similar results were obtained with PMN from a patient treated with G-CSF for aplastic anemia (data not shown). As these antibodies recognize at least three different epitopes of FcyRI,I7 these results further support the idea that PMN during G-CSF treatment indeed express the high-affinity receptor for IgG.
We next analyzed whether FcyRI was actively transcribed in PMN upon exposure to G-CSF in vivo. As a control, we used the myeloid THP-I cell line, which showed the characteristic 1.7-and 1.6-kb transcripts for F c~R I .~,~~,~~,~~ Th e 1.6-kb FcyRI transcript was only faintly visible in freshly isolated monocytes or monocytic cell line THP-1 (data not shown), but expression increased dramatically upon overnight culture with IF%-/.
These FcyRI transcripts were absent in K562. RNA isolated from PMN from four patients treated with G-CSF expressed FcyRI mRNA ofthe 1.7-kb size (Fig 2) . PMN from patient no. 5 were evaluated both before and during treatment with G-CSF, and only showed the 1.7-kb FcyRI transcript during the treatment episode. These data support the idea that FcyRI is actively transcribed in PMN upon treatment of patients with G-CSF in vivo.
Three highly homologous genes have been found to encode four distinct FcyRI transcripts. Due to this extensive homology between the three genes (>98% sequence identity), the different transcripts can only be selectively detected via RT-PCR analysis4 RT-cDNA products from three patients were used to amplify FcyRI transcripts via primers hybridizing to the first extracellular Ig-like domain (EC1) encoding region and the cytoplasmic tail encoding domain. Upon amplification two PCR products were consistently observed. The blotted PCR products were probed with different gene-specific primers. The largest (880 bp) band hybridized exclusively with an FcyRIA gene-specific primer (Fig 3A) and corre- (Fig 3B) and was recently found to constitute solely of an FcyRIB-encoded transcript. This transcript (FcyRIb2) lacks one of the extracellular domains (ie, EC3). The simultaneous expression of both these FcyRIa and FcyRlb2 products parallels our observations with other FcyRI-positive cells analyzed up to now, including monocyte^,^ U937 (Fig 3) , and THP-I cells (data not shown).
All PMN samples from patients analyzed in this study consisted of more than 95% of neutrophils, as evaluated morphologically (contaminating cells being mainly eosinophils). To exclude the possibility of monocyte contamination, causing (false-) positive PCR results, we subjected all PMN RT-cDNA samples (Fig 3) to a PCR method to detect the monocyte-specific c$ms transcript.** However, in none of our PMN samples could we identify the clfms cDNA product consistent with absent monocytes.
Functional activity of neirtrophil FORI
Binding of monomeric human IgG. FcyRI differs from both classes of low-affinity IgG receptors, FcyRIl (CD32) and FcyRIll (CDI 6), by virtue of its capacity to bind monomeric IgG with high affinity. Initially, in vivo-bound cytophilic IgG was analyzed after 3 hours of incubation of PMN in serum-free medium. After washing, bound IgG was detected using FITC-conjugated F(ab') fragments for human IgG (Fig 4) . In these experiments, more surface IgG was found on PMN during G-CSF therapy compared with that found on control PMN (mean FI, 23.9 5 7.8 SEM v 6.9 5 2.9; n = 3). Subsequently, monomeric human IgG was added, cells were incubated for another 30 minutes at 4"C, and cells were analyzed as above (Fig 4) . Thus, minimal binding of exogenous IgG was observed with control PMN (FI increased from 6.9 5 2.9 to 8.4 rt 3.3, n = 3). In contrast, G-CSF PMN bound increased amounts of monomeric IgG (FI, 23.9 & 7.8 to 45.3 5 20.8; n = 3). These data show that G-CSF PMN were capable of binding significantly (P < .OS) more human IgG than control PMN.
Enhanced cytotoxicity of PMN during in vivo application of G-CSF was observed using Daudi lymphoma cells as targets after sensitization with polyclonal rabbit antiserum.' Further experiments were performed to investigate whether these results can be extended to solid tumor cell targets, using MoAbs for sensitization. Therefore, ADCC assays of PMN against A I207 (glioma) and A43 1 (squamous cell carcinoma) cell lines were established after the sensitization of target cells with MoAb 425 to the EGF receptor. As shown in Table 2 , neutrophils during G-CSF therapy were significantly (P < .OO 1 and P < .OS) more cytotoxic to A 1207 and to A43 1, respectively, than neutrophils from healthy donors. FcyRII has been suggested to be the main trigger molecule for cytotoxicity of freshly isolated PMN, but (after in vitro induction by IFN-y) FcyRl was also shown to mediate killing of tumor cells. 
Identification OfFc receptors involved in ADCC.
For The selectivity of this inhibition for FcyRI has been shown before.,' For these blocking experiments, PMN from healthy donors were stimulated in vitro by adding conditioned medium of bladder carcinoma cell line 5637 during ADCC assays, because cytotoxicity of control PMN was too low to investigate inhibitory effects (Table 2 ). This conditioned medium (containing natural human GM-CSF ADCC of PMN from G-CSF-treated patients and from healthy donors was compared using MoAb 425 (IgG2a) to the EGF receptor for the sensitization of A1 207 (glioma) and A43 1 (squamous cell carcinoma) cell lines. The differences between PMN from G-CSF-treated patients and from health donors were significant ( P i ,001 for A1207; P < .05 for A431) for both cell lines. These blocking studies further supported cytotoxicity by PMN from G-CSF-treated patients to be mediated via FcyRI. To assess the functional role of FcyRI more directly, bispecific antibody 520C9 X 22 [F(ab), X F(ab'),] with specificities against both the tumorassociated antigen erbB2/HER-2 and Fcy RI was used. Ovarian carcinoma cells (SK-OV~), overexpressing erbB2/ HER-2, were used as targets. Assay duration was 18 hours in the presence of conditioned medium of 5637 cells for in vitro stimulation of effector cells. Control experiments with an equimolar mixture of unlinked F(ab), fragments of both parental antibodies gave only marginal levels of target killing (less than 20% of bispecific lysis). Neutrophils during G-CSF therapy were found to be significantly ( P < .05) more efficient in killing via FcyRI than PMN from healthy donors (mean of % specific lysis, 20.1 f 12. I SEM, [n = 61 v 4.1 f I .7 [n = 61, respectively) (Fig 6) . These data indicate that FcyRI on PMN may act as cytotoxic trigger molecule in a concept of targeted cytotoxicity with bispecific antibodies.
Selective ADCC via FcyRI.
DISCUSSION
Of all three classes of Fc receptors for IgG, the high-affinity receptor (FcyRI; CD64) is the one with the most restricted cellular distribution. It is constitutively expressed only on peripheral blood monocytes, on macrophages, and (albeit at very low numbers) on PMN.2 Our previous observation' that neutrophils during G-CSF therapy express large numbers of FcyRI is now confirmed in patients with a broad spectrum of hematologic and nonhematologic disorders. Originally, patients receiving chemotherapy were randomized to either subcutaneous G-CSF injections or to a control arm treated with the same chemotherapy but without G-CSF support.' FcyRI expression was found to be sig- 
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Selective ADCC of PMN via FvRI. Bispecific antibody 520C9 X 22 [F(ab'), X F(ab),] with specificities against the protooncogene product HER-S/neu (MoAb 520C9) and FcyRl (MoAb 22) was tested in an 18-hour ADCC assay against SK-ov3 targets. PMN from healthy individuals and G-CSF-receiving patients were compared using the conditioned medium of 5637 for in vitro stimulation of both effector cell populations. In control experiments with an equimolar mixture of unlinked F(ab), fragments of the parental antibodies, only marginal tumor cell lysis (less than 20% of bispecific ADCC) was observed. The results are presented as the mean f SEM of n = 6 pairs of donors. The differences between control PMN and G-CSF PMN were statistically significant (P < .05). 38 Therefore, increased FcyRI expression of PMN during G-CSF therapy may be due to its action on neutrophil progenitors in the bone marrow. Accordingly, during treatment with GM-CSF, which does not reduce the maturation time of PMN in the bone marrow,38 FcyRI expression was found not to be enhanced in a patient with cyclic neutropenia. Recently, G-CSF has been shown to induce FcyRI expression on highly enriched CD34+ bone marrow cells.39 So far, three genes (termed FcyRIA, FcyRIB, and FcyRIC) have been identified that encode four transcripts for the high-affinity receptor for IgG (FcyRI; CD64):s3* RT-PCR analysis was performed using FcyRIa-and Fcy RIblc-specific primers, respectively, to see whether also FcyRIb and FcyRIc transcripts were present in neutrophils during G-CSF therapy. These experiments clearly showed transcription of both the membrane bound isoforms, FcyRIa and FcyRIb2 (Fig 3) . In the murine system, the three-domain FcyRI (corresponding to hFcyRIa) bound IgG with high affinity, but the two-domain receptor form did not.40 Therefore, all three domains seem necessary for high-affinity binding. Up to now, the biologic role of the "two-domain'' hFcyRIb2 molecule, as well as of the two soluble forms (hFcyRIb1 and hFcyRIc), is obscure and is the subject of detailed analysis.
On myeloid cells, FcyR mediate diverse functions such as phagocytosis; the triggering of cytotoxicity; degranulation; the generation of superoxide; the release of cytokines such For personal use only. on October 30, 2017. by guest www.bloodjournal.org From as interleukin-1 (IL-l), IL-6, and tumor necrosis factor-a (reviewed in Van de Winkel and Anderson2); and the enhancement of antigen presentation4'; suggesting an important role as biologic trigger molecules. However, the precise classes or isoforms of FcyR mediating these various effects on different populations of effector cells remain to be identified for most functions. Neutrophil-mediated cytotoxicity of tumor cells was shown to be triggered via FcyRII, using either bispecific antibodies (with tumor-and FcR-directed specificities), or anti-FcR antibody-producing hybridomas as targets in reverse ADCC.33 In these assays, which most selectively engage distinct classes of FcyR, FcyRI, after in vitro induction by IFN-7, also mediates tumor cell cytotoxicity by neutrophils. Our data presented here, using bispecific antibodies and blocking antibodies to the different classes of FcyR, establish an active role of FcyRI on PMN upon in vivo application of G-CSF. The most abundantly expressed FcyR on PMN (FcyRIIIb) is a phosphatidylinosito1 (PI)-anchored molecule'.' that lacks a transmembrane portion and, therefore, is supposed to have limited capacity to transmit intracellular signals. Accordingly, FcyRIIIb did not mediate cytotoxicity in bispecific or reverse ADCC ass a y~,~~ but blocking antibodies to FcyRIII were reported to inhibit lysis of specific tumor targets.42
The biologic role of FcyRI, eg, in antigen presentation,"' and in the pathogenesis or management of i n f e~t i o n s~~,~ has been addressed in recent studies. In addition, FcyRI is an interesting molecule for the therapeutic approach of targeted cytot~xicity.'~ As shown here, G-CSF-activated neutrophils can kill a variety of solid tumor cell lines, using clinically interesting MoAbs to the proto-oncogene products erbB2/HER-2 or the EGF receptor. In addition, lysis of freshly obtained tumor cells by PMN was also shown by Cemerlic et al." The findings reported here further support the view that a combination of G-CSF and MoAbs to tumor-related epitopes may be effective in cancer therapy.
